Remepy Partners with Merck KGaA to Scale Hybrid Drug Platform in Rare Tumors

New updates have been reported about Remepy.

Remepy has entered a collaboration with Merck KGaA, Darmstadt, Germany to co-develop Hybrid Drugs, initially targeting rare tumor indications in the U.S. under selected programs. The agreement creates a framework to potentially extend Remepy’s Hybrid Drug approach across additional therapeutic areas in Merck KGaA’s portfolio, positioning Remepy’s platform as an integrated component of future combination treatments.

Remepy’s Hybrid Drugs pair conventional pharmacological agents with AI-driven, app-delivered digital protocols that provide personalized motor, cognitive, and behavioral interventions in a single prescription product. This model leverages newly clarified U.S. regulatory pathways, including FDA guidance on Prescription Drug Use-Related Software and software-as-a-medical-device drug combinations, enabling closer integration of software with drugs and aligning digital components with pharma-style development, label expansion, and reimbursement.

By embedding the digital layer into the drug itself, Remepy aims to shift digital health economics from stand-alone therapeutics into traditional pharmaceutical pricing, commercialization, and payer frameworks. Co-founder and Co-CEO Dr. Michal Tsur said the collaboration is designed to help pharma differentiate products, improve efficacy, and scale integrative treatment approaches, particularly where evidence supports combining medication with behavioral and physical interventions.

For Remepy, the partnership with a global science and technology company provides a potential pathway to broader clinical deployment, access to large therapeutic franchises, and a route to validate Hybrid Drugs in oncology and other complex diseases. If successful, the model could accelerate adoption of integrated drug–software therapies, influence future drug labels by embedding digital components, and create new value propositions for patients, payers, and pharmaceutical partners seeking outcome-enhancing adjuncts without separate digital reimbursement structures.